1. Home
  2. JG vs SKYE Comparison

JG vs SKYE Comparison

Compare JG & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aurora Mobile Limited

JG

Aurora Mobile Limited

HOLD

Current Price

$7.66

Market Cap

40.6M

Sector

Technology

ML Signal

HOLD

Logo Skye Bioscience Inc.

SKYE

Skye Bioscience Inc.

HOLD

Current Price

$1.07

Market Cap

44.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JG
SKYE
Founded
2012
2012
Country
China
United States
Employees
N/A
N/A
Industry
Computer Software: Programming Data Processing
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
40.6M
44.9M
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
JG
SKYE
Price
$7.66
$1.07
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$14.75
AVG Volume (30 Days)
7.6K
453.3K
Earning Date
03-12-2026
03-19-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$50,967,244.00
N/A
Revenue This Year
$10.90
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
20.78
N/A
52 Week Low
$5.85
$0.68
52 Week High
$20.94
$5.75

Technical Indicators

Market Signals
Indicator
JG
SKYE
Relative Strength Index (RSI) 56.74 50.92
Support Level $6.71 $0.95
Resistance Level $8.10 $1.07
Average True Range (ATR) 0.56 0.08
MACD 0.06 0.02
Stochastic Oscillator 58.89 44.19

Price Performance

Historical Comparison
JG
SKYE

About JG Aurora Mobile Limited

Aurora Mobile Ltd provides stable, and accurate developer services for educational and medical products. It is focused on providing companies with stable and efficient push notification services. It provides a comprehensive suite of services to mobile app developers in mainland China. Through its developer services, it gains access to, aggregate, cleanse, structure and encrypt vast amounts of real-time and anonymous device-level mobile behavioral data. It offers data services such as iAPP which helps the investors to analyze opportunities in the sector, Anti-fraud helps to identify fraud risks, iAudience, iZone and other related services. The company operates and generates its revenue from the People's Republic of China.

About SKYE Skye Bioscience Inc.

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Share on Social Networks: